
Abbott
Abbott is a global healthcare company spanning medical devices, diagnostics, nutrition and established pharmaceutical products.
Last updated November 10, 2026
AI crawler reads
237requests
8AI- OpenAI169
- Perplexity20
- Amazon15
- Meta14
- Shape12
- +37
- Profile
- 179
- Controversies
- 19
- JSON · MD
- 0
- First read
- Oct 29, 2026
- Latest read
- Nov 17, 2026
From this site's server log
Overview
Abbott is the corporate brand of Abbott Laboratories, a diversified healthcare company headquartered in Abbott Park, Illinois. Founded in Chicago in 1888 by physician and pharmacist Wallace Calvin Abbott, the company began by manufacturing dosimetric granules containing precise quantities of medicinal alkaloids. Its early emphasis on dosage accuracy developed into a broader business in medicines, diagnostics, nutrition and medical technology. Abbott is organized around four principal business areas: medical devices, diagnostics, nutrition and established pharmaceutical products. Its medical-device portfolio includes cardiovascular and structural-heart technologies, vascular products, electrophysiology and cardiac-rhythm-management systems, neuromodulation devices, diabetes-care technologies and other specialty devices. The company’s diagnostics business supplies laboratory systems, point-of-care instruments and rapid and molecular tests. Its nutrition activities cover infant, pediatric, adult and specialized clinical nutrition, while its established-pharmaceuticals business sells branded generic and mature medicines in numerous international markets. Several Abbott franchises have become especially prominent. FreeStyle Libre is a family of wearable glucose-monitoring systems designed to provide continuous or near-continuous glucose data through a sensor and reader or smartphone application. Ensure, Glucerna and Pedialyte are major nutrition brands serving adult, diabetes-related, hydration and pediatric needs. Similac is a leading infant-nutrition brand, while specialty formulas such as Alimentum and EleCare address selected dietary and medical requirements. In diagnostics, Abbott markets platforms such as Alinity, ARCHITECT, i-STAT and BinaxNOW. In cardiovascular care, its portfolio includes MitraClip, TriClip, vascular-intervention products, transcatheter devices and cardiac rhythm-management technologies. Aveir is part of Abbott’s leadless pacemaker portfolio. Abbott’s modern scale was built partly through acquisitions and portfolio restructuring. Important transactions included the acquisition of Ross Laboratories, the pharmaceutical business of Knoll, Solvay Pharmaceuticals, Alere and St. Jude Medical, as well as numerous device, diagnostics and biotechnology businesses. The 2016 acquisition of St. Jude Medical substantially expanded Abbott’s cardiovascular, electrophysiology, heart-failure and neuromodulation capabilities. The acquisition of Alere strengthened Abbott’s point-of-care and rapid-diagnostics activities. Abbott also developed major internal platforms, most notably FreeStyle Libre, which originated in Europe in 2014 and became one of the company’s central growth franchises. The company operates in more than 160 countries and sells to hospitals, laboratories, physicians, pharmacies, retailers, governments, insurers, employers and consumers. Its products range from highly regulated implantable devices and laboratory analyzers to over-the-counter nutrition products and consumer-oriented health technologies. This combination gives Abbott a diversified revenue base and allows it to participate in both clinical and everyday health-management markets. Abbott’s public reputation has been shaped by both innovation and regulatory scrutiny. The 2022 recall of selected powdered Similac, Alimentum and EleCare products manufactured at its Sturgis, Michigan, facility contributed to a severe United States infant-formula shortage and prompted extensive FDA investigation. Abbott has also faced litigation and product-safety disputes involving medical devices and nutrition products. At the same time, the company has emphasized patient access, decentralized testing, connected health, affordability and consumer participation in healthcare. Under Chairman and Chief Executive Officer Robert B. Ford, Abbott has continued to position itself as a science-led healthcare company whose growth is driven by diagnostics, medical devices, nutrition, diabetes management and internationally distributed pharmaceutical products.
History
Abbott began in 1888 when Wallace Calvin Abbott, a Chicago physician and drug-store proprietor, founded the Abbott Alkaloidal Company. The business initially produced medicinal products using accurately measured alkaloid granules. This focus on dosage precision was important in an era when physicians and pharmacists often had to measure active ingredients themselves. The company gradually expanded beyond its original alkaloidal products and developed a broader pharmaceutical and healthcare identity. During the early twentieth century, Abbott grew its manufacturing and research capabilities and adopted the Abbott name. The company expanded into pharmaceutical preparations, laboratory products and other medical applications. Its development was shaped by the broader professionalization of medicine, the growth of scientific drug manufacturing and increasing regulatory expectations for consistency and quality. Nutrition became a major part of Abbott's business through the acquisition of Ross Laboratories in 1964. Ross brought infant and pediatric nutrition expertise and brands that later became central to Abbott Nutrition, including Similac. Over time, Abbott expanded into adult nutrition, specialized formulas, diabetes-oriented nutrition and hydration products. Ensure, Glucerna, Pedialyte, Alimentum and EleCare became associated with different stages or specialized needs in the nutrition portfolio. Abbott's pharmaceutical portfolio expanded significantly in the second half of the twentieth century. The company acquired or developed established medicines and international pharmaceutical operations, while also building diagnostic and medical-device capabilities. In 2001, Abbott acquired Knoll, the pharmaceutical unit of BASF, adding products and research assets. The company later acquired Solvay Pharmaceuticals in 2010, strengthening its international branded-generics and established-pharmaceutical operations. Medical devices became increasingly important through a long series of acquisitions and internal developments. Abbott acquired businesses involved in vascular intervention, cardiac rhythm management, electrophysiology, neuromodulation, structural heart care and diabetes technology. The acquisition of TheraSense in 2004 helped establish the foundation for Abbott's later FreeStyle diabetes-care business. Abbott's early FreeStyle Navigator continuous glucose monitor was eventually discontinued, but lessons from that program contributed to a redesign centered on ease of use, affordability and patient convenience. FreeStyle Libre debuted in Europe in 2014. Unlike conventional glucose-monitoring routines that relied heavily on repeated finger-stick testing, Libre used a wearable sensor to provide glucose readings through a reader or compatible digital device. The platform expanded through successive generations and became one of Abbott's most important growth franchises. Abbott subsequently developed additional Libre products, professional and consumer-oriented applications, and Lingo, a glucose biosensor positioned for people interested in wellness and metabolic data. Abbott's cardiovascular and device businesses were transformed by major transactions. Abbott acquired Evalve in 2009, bringing the MitraClip transcatheter mitral-valve-repair technology into its portfolio. The company also acquired numerous cardiac-device and vascular businesses. In 2016, Abbott announced its acquisition of St. Jude Medical, which was completed in 2017. St. Jude added cardiac rhythm management, electrophysiology, structural heart, heart-failure and neuromodulation capabilities. Abbott later used these capabilities to expand products such as MitraClip, TriClip and the Aveir leadless pacemaker system. Diagnostics became another strategic pillar. Abbott acquired i-STAT and other point-of-care assets, expanded laboratory systems such as ARCHITECT and Alinity, and acquired Alere in 2017. Alere brought rapid and point-of-care testing products, including technologies that later supported Abbott's infectious-disease testing activities. During the COVID-19 pandemic, Abbott's BinaxNOW and molecular and laboratory testing products received substantial public attention and regulatory review. Abbott has also faced serious scrutiny. In 2022, the FDA investigated complaints involving infants who had consumed powdered formula manufactured at the company's Sturgis, Michigan, facility. The investigation identified Cronobacter sakazakii in environmental samples and led to recalls of selected Similac, Alimentum and EleCare products. The plant shutdown contributed to a national infant-formula shortage in the United States. The episode resulted in congressional, regulatory, legal and public criticism concerning sanitation, production controls, communication and the resilience of the infant-formula supply chain. Today, Abbott operates as a diversified healthcare company organized around medical devices, diagnostics, nutrition and established pharmaceutical products. It sells in more than 160 countries and serves both professional and consumer markets. Its strategic identity combines high-growth technologies such as FreeStyle Libre, structural-heart devices and molecular diagnostics with durable nutrition brands and established medicines. Robert B. Ford became president and chief executive officer in 2020 and chairman in 2021, succeeding Miles D. White and continuing Abbott's emphasis on innovation, portfolio diversification and global healthcare access.
- 2024
Abbott marks ten years of FreeStyle Libre
[6]Abbott highlighted the tenth anniversary of the FreeStyle Libre platform and its expansion into newer generations and related glucose technologies.
- 2022
Sturgis infant-formula recall
[8]Abbott recalled selected powdered infant formulas made at its Sturgis, Michigan, facility after an FDA investigation involving Cronobacter sakazakii.
- 2020
Robert B. Ford becomes chief executive officer
[3]Robert B. Ford succeeded Miles D. White as Abbott's president and chief executive officer.
- 2017
St. Jude Medical and Alere transactions completed
[12]The transactions materially expanded Abbott's cardiovascular, neuromodulation, point-of-care and rapid-diagnostics portfolios.
- 2016
St. Jude Medical acquisition announced
[11]Abbott announced a major transaction intended to expand its cardiovascular and neuromodulation businesses.
- 2014
FreeStyle Libre debuts in Europe
[6]Abbott launched the first FreeStyle Libre system in Europe after redesigning its approach to continuous glucose monitoring.
- 2010
Solvay Pharmaceuticals acquired
[10]The transaction expanded Abbott's established-pharmaceuticals business and international reach.
- 2009
Evalve acquired
[7]Abbott acquired Evalve, the company associated with MitraClip transcatheter mitral-valve repair technology.
- 2004
TheraSense acquired
[10]The acquisition strengthened Abbott's diabetes-care activities and contributed to the later development of FreeStyle Libre.
- 2001
Knoll pharmaceutical business acquired
[10]Abbott acquired Knoll, expanding its pharmaceutical products and research capabilities.
Products and positioning
Science-led, diversified healthcare provider combining medical technology, diagnostics, nutrition and established medicines, with a strong emphasis on chronic-disease management, cardiovascular care, infant and adult nutrition, decentralized testing and consumer health data.
Diabetes technology · 2014
FreeStyle Libre
FreeStyle Libre is Abbott's family of wearable glucose-monitoring systems. A small sensor measures glucose in interstitial fluid and transmits readings to a reader or compatible smartphone application. The platform was designed to reduce the burden of conventional finger-stick testing and to make glucose trends more visible to people with diabetes and their healthcare professionals. Successive generations have emphasized smaller sensors, longer wear periods, improved accuracy, connectivity and broader access. Abbott has also extended the technology toward consumer wellness through Lingo.
Adult nutrition
Ensure
Ensure is Abbott's adult nutrition brand, offering shakes and related products intended to provide calories, protein, vitamins and minerals. Product formulations vary by market and may target general nutritional supplementation, weight maintenance, higher protein needs or specific nutritional situations. Ensure is sold through retail, pharmacy and healthcare channels and is one of Abbott Nutrition's best-known global consumer brands.
Infant nutrition
Similac
Similac is Abbott's principal infant-formula brand in the United States and several international markets. Its portfolio includes standard infant formulas and specialized products designed for selected feeding, digestive or nutritional needs. The brand has been central to Abbott Nutrition's business for decades, while also being associated with the 2022 recall of selected powdered products manufactured at the Sturgis, Michigan, facility.
Hydration and electrolyte products
Pedialyte
Pedialyte provides oral rehydration and electrolyte products, including ready-to-drink liquids, powders and frozen formats in selected markets. The brand is widely associated with hydration support for children and adults during fluid loss. Abbott markets Pedialyte through consumer, pharmacy and healthcare channels.
Diabetes nutrition
Glucerna
Glucerna is Abbott's nutrition brand for people managing diabetes or blood-glucose concerns. Products generally emphasize controlled carbohydrate profiles, protein and nutrition designed for use alongside an individual's broader dietary and medical plan. The portfolio includes shakes, powders and other formats that vary by country.
Laboratory diagnostics
Alinity
Alinity is a family of laboratory diagnostic systems and assays used in areas such as clinical chemistry, immunoassay, hematology, blood screening and molecular diagnostics. The platform is intended to help laboratories consolidate workflows, automate testing and process high volumes of patient samples. Products and regulatory clearances differ by market.
Laboratory diagnostics
ARCHITECT
ARCHITECT is Abbott's established laboratory-instrument and assay platform. It has been used for automated immunoassay and clinical chemistry testing in hospitals, reference laboratories and other diagnostic settings. ARCHITECT remains part of Abbott's broader laboratory-diagnostics portfolio alongside newer Alinity systems.
Point-of-care diagnostics
i-STAT
i-STAT is a point-of-care testing system designed to produce near-patient blood-test results using handheld analyzers and disposable cartridges. It is used in settings such as emergency care, critical care, operating rooms, ambulances and clinics where rapid results can support immediate clinical decisions.
Rapid diagnostics
BinaxNOW
BinaxNOW is Abbott's rapid-test brand, best known for lateral-flow and antigen tests used for infectious-disease screening and diagnosis. The product family gained major visibility during the COVID-19 pandemic, when Abbott supplied rapid SARS-CoV-2 tests for professional and, in some markets, consumer use.
Structural-heart device · 2008
MitraClip
MitraClip is a catheter-based transcatheter edge-to-edge repair system for selected patients with mitral regurgitation. The device uses a clip delivered through a catheter to approximate portions of the mitral valve and reduce leakage without conventional open-heart surgery. Abbott acquired Evalve, the company that developed the technology, in 2009 and has continued to update the platform.
Structural-heart device · 2020
TriClip
TriClip is Abbott's transcatheter edge-to-edge repair system for selected patients with tricuspid regurgitation. It adapts principles developed for MitraClip to the tricuspid valve. Abbott launched versions of TriClip in European and Canadian markets before receiving United States regulatory clearance for the TriClip G4 system.
Cardiac rhythm management
Aveir
Aveir is Abbott's leadless pacemaker platform. Unlike conventional pacemakers that use a subcutaneous generator connected to transvenous leads, leadless systems are implanted within the heart. Aveir products are intended for selected patients requiring pacing, with indications, configurations and availability varying by regulatory market.
Consumer glucose biosensor · 2024
Lingo
Lingo is Abbott's consumer-oriented glucose biosensor platform. It uses wearable glucose-sensing technology and a digital application to provide information about glucose patterns and lifestyle responses. Abbott positioned Lingo as a product for people interested in health and wellness insights rather than solely as a prescription diabetes-management device.
Controversies
2024
FDA issues Class I recall for Abbott HeartMate pumps
The FDA issued its most serious recall for Abbott subsidiary Thoratec's HeartMate II and HeartMate 3 pumps, affecting nearly 14,000 devices. The devices can develop a buildup of biological material that reduces blood-flow capability; the article reports that the recall was linked by the agency to hundreds of injuries and at least 14 deaths.
2023
Lawsuit filed over PediaSure height claims
Joanne Noriega filed a proposed class action against Abbott Laboratories, alleging that the company misled consumers into believing PediaSure drinks were clinically proven to increase children's height. Abbott said the case was without merit and defended the product's nutritional claims.
2022
Sturgis infant-formula contamination investigation and recall
The FDA investigated complaints involving infants who consumed powdered formula produced at Abbott Nutrition's Sturgis, Michigan, plant. FDA investigators reported Cronobacter sakazakii in environmental samples, adverse inspection observations and company records concerning environmental contamination and product destruction. Abbott voluntarily recalled selected Similac, Alimentum and EleCare powdered formulas. The plant shutdown contributed to a severe United States infant-formula shortage and generated congressional, legal and regulatory scrutiny.
2022
Infant-formula supply shortage and government scrutiny
Because Abbott was one of the largest United States infant-formula suppliers, the Sturgis recall and production suspension had effects beyond the recalled products. The episode intensified scrutiny of industry concentration, WIC supply arrangements, production resilience, regulatory oversight and the company's crisis communications.
2022
Abbott recalls certain ready-to-feed formula products over bottle-cap sealing defect
Abbott announced a recall of some ready-to-feed liquid formula products for infants and children, including Similac and Pedialyte Electrolyte Solution. Abbott said caps on a small percentage of bottles in the recalled lots may not have sealed completely, which could result in spoilage and gastrointestinal symptoms if consumed.
2022
Shoppers Drug Mart recalls certain Abbott infant formula products
Shoppers Drug Mart locations recalled certain Abbott brand powdered infant formula products due to potential Cronobacter sakazakii and Salmonella contamination.
2022
Abbott apologizes for US baby formula shortage
Abbott CEO Robert Ford apologized to US families affected by the baby formula shortage. The article says Abbott's voluntary recall had exacerbated the shortage.
2022
Government report describes possible Abbott formula contamination
A news report citing a latest government document said investigators found that infant formula made at Abbott's Michigan facility may have been contaminated months before the recall. The article also reports that investigators said contaminants, including Cronobacter, could potentially have been transferred to formula; it does not establish that the potentially affected batch was distributed.
2022
Abbott recalls six lots of Similac Alimentum in Vietnam
Abbott Laboratories GmbH’s Hanoi representative office announced a voluntary recall in Vietnam of six lots of Similac Alimentum Eye-Q powdered infant formula because they potentially contained two kinds of dangerous bacteria. The article reports that 7,050 cartons had entered the market and that the importer notified customers about the recall.
2022
Abbott recalls three infant formula products
Abbott recalled three infant formula products after Cronobacter sakazakii was found in a non-product-contact area of a Michigan factory; the source says the products could pose a health risk to infants aged 0–6 months and that the investigation was ongoing.
Brand decisions
2026
Abbott announces planned nutrition business spin-offM&ABackground
Abbott announced plans to spin off its global nutrition business as a separately listed company. The business, which includes Similac, PediaSure, Pedialyte, Glucerna and Ensure, is expected to complete the transaction by the end of 2027.
2026
Abbott announces a baby formula spinoffM&ABackground
Abbott Laboratories announced a baby formula spinoff company.
2023
Abbott announced plans to acquire Cardiovascular SystemsM&ABackground
Abbott announced plans to acquire Cardiovascular Systems for $20 per share, an approximately $890 million deal. The companies said the transaction would require regulatory and shareholder approvals; it had not yet been completed.
2023
Abbott completes acquisition of Bigfoot BiomedicalM&ABackground
Abbott announced that it completed its acquisition of Bigfoot Biomedical, which became a wholly owned subsidiary of Abbott upon completion.
2023
Abbott completes acquisition of Cardiovascular Systems, Inc.M&ABackground
Abbott announced it completed the acquisition of Cardiovascular Systems, Inc. (CSI), which became Abbott’s wholly owned subsidiary upon completion.
Recent events
- Unconfirmed
Abbott announces planned nutrition business spin-off[13]
Abbott announced plans to spin off its global nutrition business as a separately listed company. The business, which includes Similac, PediaSure, Pedialyte, Glucerna and Ensure, is expected to complete the transaction by the end of 2027.
Abbott announces a baby formula spinoff[14]
Reported
Abbott Laboratories announced a baby formula spinoff company.
Abbott cuts its 2026 sales growth forecast[38]
Reported
Abbott cut its 2026 sales growth forecast to about 6%, from its previous expectation of 6.5% to 7.5%.
FDA issues Class I recall for Abbott HeartMate pumps[24]
Reported
The FDA issued its most serious recall for Abbott subsidiary Thoratec's HeartMate II and HeartMate 3 pumps, affecting nearly 14,000 devices. The devices can develop a buildup of biological material that reduces blood-flow capability; the article reports that the recall was linked by the agency to hundreds of injuries and at least 14 deaths.
FDA approves Abbott's TriClip system for tricuspid regurgitation[39]
Reported
The US Food and Drug Administration approved Abbott's TriClip transcatheter edge-to-edge repair system for treatment of tricuspid regurgitation. Abbott announced the approval on April 2, 2024.
Abbott launches Protality protein shake[40]
Reported
Abbott said it launched a protein shake under its new Protality brand, intended to help adults looking to lose weight maintain muscle mass.
Abbott launches FreeStyle LibreLink app in India[41]
Reported
Abbott launched the FreeStyle LibreLink app in India. The app lets users of the FreeStyle Libre system view glucose readings on their mobile phones without pricking.
FDA approves Tibsovo for certain patients with MDS[42]
Reported
The FDA approved Servier’s Tibsovo to treat adults with relapsed or refractory MDS with an IDH1 mutation, making it the first targeted therapy approved for this indication. The regulator also approved the Abbott RealTime IDH1 Assay as a companion diagnostic for identifying eligible patients.
Abbott raises 2023 earnings guidance[43]
Reported
Abbott raised and narrowed its adjusted diluted earnings-per-share guidance for 2023 to $4.42–$4.46, from its previous range of $4.30–$4.50.
Abbott completes acquisition of Bigfoot Biomedical[16]
Reported
Abbott announced that it completed its acquisition of Bigfoot Biomedical, which became a wholly owned subsidiary of Abbott upon completion.
Sources103 sources
- 1Abbott: Promise for Life, The Story of Abbottabbott.com
- 2Abbott Executive Leadershipabbott.com
- 3Robert B. Ford biographyabbott.com
- 4Abbott Executive Teamabbott.com
- 5Abbott Products and Solutionsabbott.com
- 6FreeStyle Libre: How a Diabetes Breakthrough Was Bornabbott.com
- 7The MitraClip Storyabbott.com
- 8FDA Investigation of Cronobacter Infections: Powdered Infant Formulafda.gov
- 9Abbott Fourth-Quarter and Full-Year 2024 Resultsabbott.com
- 10Abbott Laboratoriesen.wikipedia.org
- 11St. Jude Medical acquisition announcedabbott.com
- 12St. Jude Medical and Alere transactions completedabbott.com
- 13Abbott announces planned nutrition business spin-offstock.jrj.com.cn
- 14Abbott announces a baby formula spinoffnews.google.com
- 15Abbott announced plans to acquire Cardiovascular Systemsfiercebiotech.com
- 16Abbott completes acquisition of Bigfoot Biomedicalprnewswire.com
- 17Abbott completes acquisition of Cardiovascular Systems, Inc.prnewswire.com
- 18Infant-formula supply shortage and government scrutinyapnews.com
- 19Lawsuit filed over PediaSure height claimsdunyanews.tv
- 20Lawsuit filed over PediaSure height claimsparentherald.com
- 21Lawsuit filed over PediaSure height claimslawstreetmedia.com
- 22Lawsuit filed over PediaSure height claimslawstreetmedia.com
- 23Lawsuit filed over PediaSure height claimslawstreetmedia.com
- 24FDA issues Class I recall for Abbott HeartMate pumpschicago.suntimes.com
- 25Abbott recalls certain ready-to-feed formula products over bottle-cap sealing defectyahoo.com
- 26Abbott recalls certain ready-to-feed formula products over bottle-cap sealing defectfinance.qianlong.com
- 27Shoppers Drug Mart recalls certain Abbott infant formula productsinfotel.ca
- 28Abbott apologizes for US baby formula shortageradio.wpsu.org
- 29Abbott apologizes for US baby formula shortagetimesofindia.indiatimes.com
- 30Abbott apologizes for US baby formula shortagejdsupra.com
- 31Government report describes possible Abbott formula contaminationsc.stock.cnfol.com
- 32Government report describes possible Abbott formula contaminationktvu.com
- 33Abbott recalls six lots of Similac Alimentum in Vietnamnews.tuoitre.vn
- 34Abbott recalls three infant formula productsilonghua.sznews.com
- 35Abbott recalls three infant formula productsnews.hexun.com
- 36Vietnam orders recall of certain Abbott formula productse.vnexpress.net
- 37Abbott's Shanghai entity fined over advertising violationsbaby.sina.com.cn
- 38雅培下调2026年销售增长预期rte.ie
- 39FDA批准Abbott的TriClip系统用于治疗三尖瓣反流hcplive.com
- 40雅培推出 Protality 蛋白奶昔yahoo.com
- 41Abbott在印度推出FreeStyle LibreLink应用thehindu.com
- 42FDA批准Tibsovo用于部分骨髓增生异常综合征患者pmlive.com
- 43Abbott 上调 2023 年业绩指引fiercebiotech.com
- 44雅培在印度推出Vertigo Coach应用biospectrumindia.com
- 45Abbott与Norton Healthcare启动临床研究计划finanznachrichten.de
- 46雅培在英国推出整合于胰岛素输送系统的 FreeStyle Libre 3fiercebiotech.com
- 47雅培宣布投资建设俄亥俄州配方产品工厂thomasnet.com
- 48Abbott在美国推出Eterna脊髓刺激器fiercebiotech.com
- 49雅培荣获三项 CES 2023 创新奖commondigital.commonperu.com
- 50FDA批准Abbott的Proclaim Plus脊髓刺激系统prnewswire.com
- 51雅培公布第二季度业绩chicagotribune.com
- 52亚培家用新冠快筛试剂宣布开卖setn.com
- 53FDA批准Abbott Portico with FlexNav经导管主动脉瓣置换系统medscape.com
- 54雅培推出用于治疗婴儿PDA的植入式医疗器械business-standard.com
- 55雅培停止格尼新冠检测组装厂运营fox32chicago.com
- 56Abbott 在美国推出 NeuroSphere Virtual Clinicselectscience.net
- 57Abbott荣获美国国务卿卢旺达创新奖rnanews.com
- 58Abbott 向学校和工作场所提供 BinaxNOWnbcnewyork.com
- 59FDA批准Abbott HeartMate 3用于儿科患者dicardiology.com
- 60雅培在加拿大推出 Similac Pro-Advancedairyreporter.com
- 61雅培在印度推出FreeStyle Libremoneycontrol.com
- 62Abbott公布2020年第三季度业绩并上调业绩指引prnewswire.com
- 63FDA授权雅培BinaxNOW新冠抗原检测finanznachrichten.de
- 64FDA批准Abbott Patient Controller应用用于兼容的Apple智能手机ptproductsonline.com
- 65FDA批准Abbott Gallant ICD和CRT-D设备finanznachrichten.de
- 66雅培将部分经销渠道转移至新经销商finance.sina.com.cn
- 67雅培宣布计划提高每日检测产品产量yahoo.com
- 68Dignity Health在北加州推出快速新冠检测kcra.com
- 69雅培推出快速新冠病毒检测产品ktrh.iheart.com
- 70FDA授权雅培新冠病毒检测ibtimes.com
- 71Abbott launches quadrivalent influenza vaccine in Indiathehindubusinessline.com
- 72Abbott 的 Gallant 设备获得 CE 标志prnewswire.com
- 73FDA批准Abbott HeartMate 3的替代植入手术方式prnewswire.com
- 74雅培与Omada合作通过糖尿病护理项目提供FreeStyle Librefiercebiotech.com
- 75🙌🏻freerepublic.com
- 76Abbott Announces Recall of Infant Formula Over Defective Caps | Physicians Weeklyphysiciansweekly.com
- 77Abbott apologises for baby formula shortage in USarticle.wn.com
- 78Abbott apologizes for US baby formula shortageeconomictimes.indiatimes.com
- 79Abbott CEO apologises for US baby formula shortage - Jamaica Observerjamaicaobserver.com
- 80Abbott CEO Apologizes for Baby Formula Shortages; Experts Weigh in on Crisistheepochtimes.com
- 81Abbott CEO apologizes for the formula shortage as the first overseas shipment arriveskvnf.org
- 82Abbott finishes India recall of baby formula products made in US - BusinessTodaybusinesstoday.in
- 83Abbott introduces NeuroSphere Virtual Clinic, first-of-its-kind remote neuromodulation patient-care technology in the UKselectscience.net
- 84Abbott launches new device in India for treatment of premature babies, newborns with heart openingsaninews.in
- 85Abbott Recalls Certain Ready-to-Feed Liquid Productsfinanznachrichten.de
- 86Abbott Recalls Formula Powder After Pathogens Detectedpowderbulksolids.com
- 87Abbott recalls several ready-to-feed liquid baby formulafox32chicago.com
- 88Abbott recalls several ready-to-feed liquid baby formulafox35orlando.com
- 89Abbott recalls some liquid baby formula over bottle defectnews.tuoitre.vn
- 90Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technologyfinanznachrichten.de
- 91Abbott voluntarily recalls some ready-to-feed liquid products due to faulty bottle capstampabay28.com
- 92Abbott's spinal cord stimulators score FDA approval to treat nonsurgical back painfiercebiotech.com
- 93FDA Approves Abbott's 5-minute Coronavirus Testfinanznachrichten.de
- 94FDA Approves Abbott's Amplatzer Amulet for Atrial Fibrillationmedscape.com
- 95FDA approves Abbott's dissolving stent for blocked arteries below the kneefiercebiotech.com
- 96FDA Approves Abbott's Novel Dissolvable Stent Therapy for Peripheral Artery Disease | HCPLivehcplive.com
- 97FDA approves inexpensive COVID-19 test that provides results in 15 minutesphillyvoice.com
- 98FDA approves less invasive surgical approach for Abbott's heart pump to help patients avoid open heart surgeryselectscience.net
- 99FDA Approves Less Invasive Surgical Approach for HeartMate 3 Heart Pumpdicardiology.com
- 100FDA approves Tibsovo for treatment of advanced myelodysplastic syndromeshealio.com
- 101FDH: Abbott Recalls Baby Formula Over Spoilage Concernswqcs.org
- 102Shoppers Drug Mart in Canada Recalls Infant Formula Milk Sold in Error Onlineparentherald.com
- 103Shoppers Drug Mart recalls several powdered infant formula products | CBC Newscbc.ca
Cite this profile: Cite the canonical profile. /brandpedia/abbott · Editorial policy · How profiles are compiled